BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9546133)

  • 1. [A case of poorly differentiated adenocarcinoma of prostate with neuroendocrine differentiation].
    Miyoshi Y; Inoue Y; Matsuzaki J; Fukuda M; Satomi Y; Akahane H; Saito S
    Hinyokika Kiyo; 1998 Feb; 44(2):113-6. PubMed ID: 9546133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A case of prostate cancer treated with combined androgen-blockade].
    Kurita M; Kato Y; Tamura Y; Suzuki K; Yamanaka H
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):307-10. PubMed ID: 10700907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment: a case report].
    Matsumoto Y; Mibu H; Kagebayashi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):813-5. PubMed ID: 15628545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuroendocrine differentiation in adenocarcinoma of the prostate during hormonal treatment : a case report].
    Segawa N; Inamoto T; Ibuki N; Mizutani Y; Azuma H; Tsuji M; Katsuoka Y
    Hinyokika Kiyo; 2010 Jan; 56(1):49-54. PubMed ID: 20104011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
    Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Giant prostate carcinoma treated effectively with endocrine therapy: case report].
    Masue N; Hasegawa Y
    Hinyokika Kiyo; 2007 Feb; 53(2):133-5. PubMed ID: 17352166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined small-cell carcinoma/adenocarcinoma of prostate: report of two cases].
    Sakuma T; Yoshida T; Ohashi H; Nishimura K; Kawano K
    Hinyokika Kiyo; 2007 Jul; 53(7):489-92. PubMed ID: 17702184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of completely responding stage D2 prostatic cancer with no evidence of disease 14 years after diagnosis].
    Tsuzuki M; Kawakami S; Yonese J; Ueda T; Kageyama S; Yamauchi T; Kawai T
    Hinyokika Kiyo; 1994 Sep; 40(9):837-40. PubMed ID: 7801848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
    Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
    Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Neuroendocrine differentiation and metastasized to brain stem, intraorbit and base of tongue in prostate cancer during hormonal treatment: a case report].
    Sugi M; Yanishi M; Shimada O; Kawakita S; Murota T; Shikata N
    Hinyokika Kiyo; 2008 May; 54(5):373-6. PubMed ID: 18546865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prostatic adenocarcinoma with neuroendocrine differentiation of the small cell type].
    Rimoldi DA; Antonio Costa J; Roveto S; Rivero O
    Medicina (B Aires); 2001; 61(3):322-4. PubMed ID: 11474882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pretreatment with chlormadinone acetate in prostate cancer patients treated with a luteinizing hormone-releasing hormone analogue].
    Yamamoto A; Sumiyoshi Y; Miyake N; Yokozeki H; Kanayama H; Kagawa S
    Hinyokika Kiyo; 1998 Aug; 44(8):557-63. PubMed ID: 9783191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Small cell carcinoma of the prostate: a case report].
    Yamamoto N; Kinoshita H; Inoue T; Kawakita S; Oguchi N; Muguruma K; Kawa G; Sakaguchi Y; Adachi Y; Sakaida N; Uemura Y; Matsuda T
    Hinyokika Kiyo; 2007 Sep; 53(9):665-9. PubMed ID: 17933147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
    Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
    Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A case of prostate cancer with cyst formation].
    Ishida K; Kubota Y; Takada T; Yamada T; Nakano M; Takahashi Y; Ishihara S; Deguchi T
    Hinyokika Kiyo; 2003 Apr; 49(4):235-7. PubMed ID: 12784721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
    Nemoto K; Tomita Y
    Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive expression analysis of L-dopa decarboxylase and established neuroendocrine markers in neoadjuvant hormone-treated versus varying Gleason grade prostate tumors.
    Wafa LA; Palmer J; Fazli L; Hurtado-Coll A; Bell RH; Nelson CC; Gleave ME; Cox ME; Rennie PS
    Hum Pathol; 2007 Jan; 38(1):161-70. PubMed ID: 16997353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.
    Bonkhoff H
    Prostate Suppl; 1998; 8():18-22. PubMed ID: 9690659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.